Skip to main content
SpringerLink
Log in

Therapeutic Complement Inhibition

  • Chapter
Multiple Organ Failure

  • 362 Accesses

Abstract

Excessive complement activation significantly contributes to the pathogenesis of a large number of inflammatory diseases, including ischemia/reperfusion injury, sepsis, and multiple organ failure syndrome. Current strategies to interfere with the deleterious action of complement include the application of endogenous soluble complement inhibitors (C1 inhibitor, recombinant soluble complement receptor 1-rsCR1), administration of antibodies, blocking key proteins of the cascade reaction (e.g., C5), neutralizing the action of the complement-derived anaphylatoxin C5a, or interfering with complement receptor 3 (CR3, CD18/11b)-mediated adhesion of inflammatory cells to the vascular endothelium. Incorporation of membrane-bound complement regulators (DAF-CD55, MCP-CD46, CD59) has provided a major step forward in protecting xenografts from hyperacute rejection. Numerous animal studies and first clinical trials strongly suggest that complement inhibition is a suitable novel therapeutic approach to preventing inflammatory disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Müller-Eberhard HJ: Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57: 321–347.

    Article  PubMed  Google Scholar 

  2. Rother K, Till GO, Hänsen GM: The Complement System, 2nd rev ed., New York, Springer, 1998

    Book  Google Scholar 

  3. Turner MW: Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996; 17: 532–540.

    PubMed  CAS  Google Scholar 

  4. Hugli TE: Biochemistry and biology of anaphylatoxins. Complement 1986; 3: 111–127.

    PubMed  CAS  Google Scholar 

  5. Morgan BP, Harris CL: omplement Regulatory Proteins. San Diego, Academic, 1999

    Google Scholar 

  6. Dalmasso AP: Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab 1986; 24: 123–183.

    Article  CAS  Google Scholar 

  7. Morgan BP: Complement: Clinical Aspects and Relevance to Disease. New York, Harcourt Brace Jovanovich, 1990.

    Google Scholar 

  8. Volanakis JE, Frank MM: The Human Complement System in Health and Disease. New York, Marcel Dekker, 1998

    Google Scholar 

  9. Zilow G, Sturm JA, Rother U, et al: Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 1990; 79: 151–157.

    Article  PubMed  CAS  Google Scholar 

  10. Mollnes TE, Fosse E: The complement system in trauma-related and ischemic tissue damage: a brief review. Shock 1994; 2: 301–310.

    Article  PubMed  CAS  Google Scholar 

  11. Lucchesi BR, Kilgore KS: Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 1997; 38: 27–42.

    Article  PubMed  CAS  Google Scholar 

  12. DeBoer JP, Creasey AA, Chang A, et al: Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 1993; 61: 4293–4301.

    PubMed  Google Scholar 

  13. Hack CE, Nuijens JH, Felt-Bersma RJ, et al: Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86: 20–26.

    Article  PubMed  CAS  Google Scholar 

  14. Colman RW: The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207–1209.

    Article  PubMed  CAS  Google Scholar 

  15. Hazelzet JA, deGroot R, vanMierlo G, et al: Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66: 5350–5356.

    PubMed  CAS  Google Scholar 

  16. Acioli JM, Isobe M, Kawasaki S: Early complement system activation and neutophil priming in acute pancreatitis: participation of trypsin. Surgery 1997; 122: 909–917.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson RJ: Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance. Nephrol Dial Transplant 1994; 9(Suppl 2): 36–45.

    PubMed  Google Scholar 

  18. Gardinali M, Circardi M, Agostoni A, et al: Complement activation in extracorporeal circulation: physiological and pathological implications. Pathol Immunopathol Res 1986; 5: 352–370.

    Article  PubMed  CAS  Google Scholar 

  19. Janatova J, Cheung AK, Parker CJ: Biomedical polymers differ in their capacity to activate complement. Complement Inflamm 1991; 8: 61–69.

    PubMed  CAS  Google Scholar 

  20. Cheung AK, Parker CJ, Hohnholt M: Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994; 46: 1680–1687.

    Article  PubMed  CAS  Google Scholar 

  21. Kirschfink M, Kovacs B, Mottaghy K: Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ Shock 1993; 40: 221–226.

    PubMed  CAS  Google Scholar 

  22. Mollnes TE: Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 1997; 14: 24–29.

    PubMed  CAS  Google Scholar 

  23. Cooper NR, Nemerow GR, Mayes JT: Methods to detect and quantitate complement activation. Springer Semin Immunopathol 1983; 6: 195–212.

    PubMed  CAS  Google Scholar 

  24. Kirschfink M: The clinical laboratory: testing the complement system. In: Rother K, Till GO, Hänsen GM (eds) The Complement System, 2nd rev ed. New York, Springer, 1998; 522–547.

    Chapter  Google Scholar 

  25. Gama deAbreu M, Kirschfink M, Quintel M, et al: White blood cell counts and plasma C3a have synergistic predictive value in patients at risk for acute respiratory distress syndrome. Crit Care Med 1998; 26: 1040–1048.

    Article  Google Scholar 

  26. Hecke F, Schmidt U, Kola A, et al: Circulating complement proteins in multiple trauma patients: correlation with injury severity, development of sepsis, and outcome. Crit Care Med 1997; 25: 2015–2024.

    Article  PubMed  CAS  Google Scholar 

  27. Kirschfink M, Wienert K, Rother K, et al: Complement activation in renal allograft recipients. Transplant Proc 1992; 24: 2556–2557.

    PubMed  CAS  Google Scholar 

  28. Hartmann H, Lubbers B, Casaretto M, et al: Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J Immunol Methods 1993; 166: 35–44.

    Article  PubMed  CAS  Google Scholar 

  29. Stove S, Welte T, Wagner TO, et al: Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1996; 3: 175–183.

    PubMed  CAS  Google Scholar 

  30. Asghar SS: Pharmacological manipulation of complement system. Pharmacol Rev 1984; 36: 223–244.

    PubMed  CAS  Google Scholar 

  31. Kirschfink M: Controlling the complement system in inflammation. Immunopharmacology 1997; 38: 51–62.

    Article  PubMed  CAS  Google Scholar 

  32. Liszewski M-K, Atkinson JP: Novel complement inhibitors. Exp Opin Invest Drugs 1998; 7: 323–332.

    Article  CAS  Google Scholar 

  33. Makrides SC: Therapeutic inhibition of the complement system. Pharmacol Rev 1998; 50: 59–87.

    PubMed  CAS  Google Scholar 

  34. Tosi M, Duponchel C, Bourgare P, et al: Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene 1986; 42: 265–272.

    Article  PubMed  CAS  Google Scholar 

  35. Sim RB, Reboul A, Arlaud GJ, et al: Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett 1979; 97: 111–115.

    Article  PubMed  CAS  Google Scholar 

  36. Forbes CD, Pensky J, Ratnoff OD: Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum CI inactivator. J Lab Clin Med 1970; 76: 809–815.

    PubMed  CAS  Google Scholar 

  37. Rataoff OD, Pensky J, Opton D, et al: The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C’lr subcomponent of the first component of complement by serum C’l esterase inhibitor. J Exp Med 1969; 129: 315–331.

    Article  Google Scholar 

  38. Ranby M, Bergsdorf N, Nilsson T: Enzymatic properties of the one-and two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175–183.

    Article  PubMed  CAS  Google Scholar 

  39. Perlmutter DH, Glover GI, Rivetoa M, et al: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87: 3753–3757.

    Article  PubMed  CAS  Google Scholar 

  40. Brower MS, Harpel PC: Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 9849–9854.

    PubMed  CAS  Google Scholar 

  41. Davis AE III: C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628.

    Article  PubMed  CAS  Google Scholar 

  42. Faymonville ME, Micheels J, Bodson L, et al: Biochemical investigations after burning injury: complement system, prote-ase-antiprotease balance and acute-phase reactants. Burns 1987; 13: 26–33.

    Article  CAS  Google Scholar 

  43. Nürnberger W, Michelmann I, Petrik K, et al: Activity of C1 esterase inhibitor in patients with Yascukr leak syndrome after bone marrow tomnsplantation. Ann Hematol 1993; 67: 17–21.

    Article  PubMed  Google Scholar 

  44. Bering R, Ohkson K: Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis. J Gastroenterol 1996; 31: 702–709.

    Article  Google Scholar 

  45. Mikkonen R, Aronen HJ, Kivisaari L, et al: Plasma levels of prekallikrein, alpha-2-macroglobulin and C1-esterase inhibitor in patients with urticarial reaction to contrast media. Acta Radiol 1997; 38: 466–473

    PubMed  CAS  Google Scholar 

  46. Gerlach M, Fohre B, Keh D, et al: Global and extended coagulation monitoring during extracorporeal lung assist with hepaiin-coated systems in ARDS patients. Int J Artif Organs 1997; 20: 29–36.

    PubMed  CAS  Google Scholar 

  47. Kirschfink M, Nürnberger W: Cl inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999; 36: 225–232.

    Article  PubMed  CAS  Google Scholar 

  48. Guerrero R, Velasco F, Rodriguez M, et al: Endotoxin-induced pulmonary dysfunction is prevented by Cl-esterase inhibitor. J Clin Invest 1993; 91: 2754–2760.

    Article  PubMed  CAS  Google Scholar 

  49. Scherer RU, Giebler RM, Schmidt U, et al: he influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. oSemin Thromb Hemost 1996; 22: 357–366.

    Article  CAS  Google Scholar 

  50. Fischer MB, Prodeus AP, Nicholson-Weller A, et al: Increased susceptibility to endotoxin shock in complement C3-and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997; 159: 976–982.

    PubMed  CAS  Google Scholar 

  51. Jansen PM, Eisele B, deJong IW, et al: Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160: 475–484.

    PubMed  CAS  Google Scholar 

  52. Hack GE, Voerman HJ, Eisele B, et al: C1-esterase inhibitor substitution in sepsis [letter]. Lancet 1992; 339: 378.

    Article  PubMed  CAS  Google Scholar 

  53. Walger P, Fronhoffs S, Steuer K, et al: The effect of C1-esterase inhibitor in five patients with streptococcal toxic syndrome. Ann Hematol 1997; 74(Suppl III): A160.

    Google Scholar 

  54. Goodman AJ, Bird NC, Johnson AG: Antiprotease capacity in acute pancreatitis. Br J Surg 1986; 73: 796–798.

    Article  PubMed  CAS  Google Scholar 

  55. Yamaguchi H, Kimura T, Mimura K, et al: Activation of proteases in cerulein-induced pancreatitis. Pancreas 1989; 4: 565–571.

    Article  PubMed  CAS  Google Scholar 

  56. Ruud TE, Aasen AO, Stadaas JO, et al: Effects on peritoneal proteolysis and hemodynamics of prophylactic and therapeutic infusions of high doses of aprotinin in experimental acute pancreatitis. Scand J Gastroenterol 1986; 21: 1011–1017.

    Article  PubMed  CAS  Google Scholar 

  57. Yamaguchi H, Weidenbach H, Luhrs H, et al: Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 1997; 40: 531–535.

    PubMed  CAS  Google Scholar 

  58. Testoni PA, Cicardi M, Bergamaschini L, et al: Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42: 301–305.

    Article  PubMed  CAS  Google Scholar 

  59. Niederau C, Brinsa R, Niederau M, et al: Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 1995; 17: 189–196.

    PubMed  CAS  Google Scholar 

  60. Kochilas L, Campbell B, Scalia R, et al: Beneficial effects of C1 esterase inhibitor in murine traumatic shock. Shock 1997; 8: 165–169.

    Article  PubMed  CAS  Google Scholar 

  61. Radke A, Mottaghy K, Goldmann Ch, et al: C1-Inhibitor prevents capillary leakage after thermal teuma. Crit Care Med 2000 (in press).

    Google Scholar 

  62. Khorram-Sefat R, Goldmann C, Radke A, et al: The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock 1998; 9: 101–108.

    Article  PubMed  CAS  Google Scholar 

  63. Jostkleigrewe F, Brandt KA, Janssen AC: C1-esterase inhibitor (C1-INH) as adjuvant therapy for septic shock following severe thermal trauma. Ann Hematol 1997; 74(Suppl III): A159.

    Google Scholar 

  64. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735–1742.

    PubMed  CAS  Google Scholar 

  65. Thijs LG, Hack CE, Strack van Schijndel RJ, et al. Activation of the complement system during immunotherapy with recombinant IL-2: relation to the development of side effects. J Immunol 1990; 144: 2419–2424.

    PubMed  CAS  Google Scholar 

  66. Ogilvie AC, Baars JW, Eerenberg AJ, et al: A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. Br J Cancer 1994; 69: 596–598.

    Article  PubMed  CAS  Google Scholar 

  67. Nürnberger W, Heying R, Burdach S, et al: C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 1997; 75: 95–101.

    Article  PubMed  Google Scholar 

  68. Stieh J, Harding P, Scheewe J, et al: Capillary leak syndrom after open heart surgery for congenital heart defects: therapy with C1-inhibitor. Biomed Progr 1996; 9: 13–16.

    Google Scholar 

  69. Buerke M, Murohara T, Lefer AM: Cardioprotective effects of a CI esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91: 393–402.

    Article  PubMed  CAS  Google Scholar 

  70. Horstiek G, Heimann A, Götze O, et al: Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997; 95: 701–708.

    Article  Google Scholar 

  71. Bauernschmitt R, Bohrer H, Hagl S: Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998; 24: 635–638.

    Article  PubMed  CAS  Google Scholar 

  72. Salvatierra A, Velasco F, Rodriguez M, et al: C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in die dog. Am J Respir Crit Care Med 1997; 155: 1147–1154.

    Article  PubMed  CAS  Google Scholar 

  73. Graeter T, Demertzis S, Scherer M, et al: Amelioration of ischemia/reperfusion injury with Cl-esterase inhibitor in a sheep lung transplant model. Ann Hematol 1997; 74(Suppl III): A156.

    Google Scholar 

  74. Lehmann TG, Heger M, Münch S, et al: Complement inhibition by C1-esterase inhibitor reduces microvascular disturbance after warm hepatic ischemia. Langenbecks Arch Chir 1999 (in press).

    Google Scholar 

  75. Hentjes B, Jankowski M, Vangerow B, et al: C1-esterase-inhibitor levels in patients with and without reperfusion injury following lung transplantation (LTx). Ann Hematol 1997; 74(Suppl III): A157.

    Google Scholar 

  76. Fearon DT: Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979; 76: 5867–5871.

    Article  PubMed  CAS  Google Scholar 

  77. Weisman HF, Bartow T, Leppo MK, et al: Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 1990; 103: 64–72.

    PubMed  CAS  Google Scholar 

  78. Fearon DT: Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clin Exp Immunol 1991; 86(Suppl 1): 43–46.

    PubMed  CAS  Google Scholar 

  79. Weisman HF, Bartow T, Leppo MK, et al: Soluble human complement receptor type 1: in vivo inhibitor of complement luppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146–151.

    Article  PubMed  CAS  Google Scholar 

  80. Hill J, Lindsay TF, Ortiz F, et al: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia/reperfusion in the rat. J Immunol 1992; 149: 1723–1728.

    PubMed  CAS  Google Scholar 

  81. Jaeschke H, Farhood A, Bautista AP, et al: Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol 1993; 264: 801–809.

    Google Scholar 

  82. Lehmann TG, Koeppel TA, Kirschfink M, et al: Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 1998; 66: 717–722.

    Article  PubMed  CAS  Google Scholar 

  83. Chavez-Cartaya RE, DeSola GP, Wright L, Jamieson NV, White DJ: Regulation of the complement cascade by soluble complement receptor type 1: protective effect in experimental liver ischemia and reperfusion. Transplantation 1995; 59: 1047–1052.

    Article  PubMed  CAS  Google Scholar 

  84. Mulligan MS, Yeh GC, Rudolph AR, Ward PA: Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury. J Immunol 1992; 148: 1479–1485.

    PubMed  CAS  Google Scholar 

  85. Rabinovici R, Yeh CG, Hillegass LM, et al: Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992; 149: 1744–1750.

    PubMed  CAS  Google Scholar 

  86. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR: The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5: 1888–1894.

    PubMed  CAS  Google Scholar 

  87. Piddlesden SJ, Storch MK, Hibbs M, et al: Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152: 5477–5484.

    PubMed  CAS  Google Scholar 

  88. Maka Y, Marsh HC, Scesney SM, et al: Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation. Transplantation 1997; 64: 1248–1255.

    Article  Google Scholar 

  89. Pierre AF, Xavier AM, Liu M, et al: Effect of complement inhibition with soluble complement receptor 1 on pig allotrans-plant lung function. Transplantation 1998; 66: 723–732.

    Article  PubMed  CAS  Google Scholar 

  90. Goodfellow RM, Williams AS, Levin JL, et al: Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 1997; 110: 45–52.

    Article  PubMed  CAS  Google Scholar 

  91. Keshavjee RD, Zamora MR, Schulman L, et al: Inhibition of complement in human lung transplant reperfusion injury: a multicenter clinical trial. J Heart Lung Transplant 1998; 17: 43A.

    Google Scholar 

  92. Kalli KR, Hsu PH, Bartow TJ, et al: Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab)2 chimeric complement inhibitor. J Exp Med 1991; 174: 1451–1460.

    Article  PubMed  CAS  Google Scholar 

  93. Makrides SC, Nygren PA, Andrews B, et al: Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 1996; 277: 534–542.

    PubMed  CAS  Google Scholar 

  94. Scesney SM, Makrides SC, Gosselin ML, et al: soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur J Immunol 1996; 26: 1729–1735.

    Article  PubMed  CAS  Google Scholar 

  95. Gralinski MR, Wiater BC, Assenmacher AN, et al: Selective inhibition of the alternative complement pathway by sCR1 [des-LHR-A] protects the rabbit isolated heart from human complement-mediated damage. Immunopharmacology 1996; 34: 79–88.

    Article  PubMed  CAS  Google Scholar 

  96. Akahori T, Yuzawa Y, Nishikawa K, et al: Role of a sialyl Lewis(x)-like epitope selectively expressed on vascular endothelial cells in local skin inflammation of the rat. J Immunol 1997; 158: 5384–5392.

    PubMed  CAS  Google Scholar 

  97. Lowe JB, Ward PA: Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest 1997; 100: S47–S51.

    PubMed  CAS  Google Scholar 

  98. Hsueh W, Sun X, Rioja LN, et al: The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990; 70: 309–314.

    PubMed  CAS  Google Scholar 

  99. Vakeva AP, Agah A, Rollins SA, et al: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259–2267.

    Article  PubMed  CAS  Google Scholar 

  100. Wang Y, Hu Q, Madri JA, et al: Amelioration of lupuslike autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563–8568.

    Article  PubMed  CAS  Google Scholar 

  101. Wang Y, Rollins SA, Madri JA, et al: Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955–8959.

    Article  PubMed  CAS  Google Scholar 

  102. Thomas TC, Rollins SA, Rother RP, et al: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389–1401.

    Article  PubMed  CAS  Google Scholar 

  103. Rollins SA, Rinder HM, Rinder CS, et al: A humanized anti-C5 scFv blocks platelet and leukocyte activation and exhibits prolonged pharmacokinetics and pharmacodynamics in human. Exp Clin Immunogent 1997; 14: 36A.

    Google Scholar 

  104. Rollins SA, Fitch JCK, Sherman S, et al: Anti-C5 single chain antibody therapy blocks complement and leukocyte activation and reduces myocardial tissue damage in CBP patients. Mol Immunol 1998; 35: 397A.

    Article  Google Scholar 

  105. Morikis D, Assa-Munt N, Sahu A, et al: Solution structure of Compstatin, a potent complement inhibitor. Protein Sci 1998; 7: 619–627.

    Article  PubMed  CAS  Google Scholar 

  106. Nilsson B, Larsson R, Hong J, et al: Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998; 92: 1661–1667.

    PubMed  CAS  Google Scholar 

  107. Fiane AE, Mollnes TE, Videm V, et al: Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin. Transplant Proc 1999; 31: 934–935.

    Article  PubMed  CAS  Google Scholar 

  108. Biesecker G, Dihel L, Enney K, et al: Derivation of RNA aptamer inhibitors of human C5. Mol Immunol 1998; 35: 371A.

    Article  Google Scholar 

  109. Stevens JH, O’Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 77: 1812–1816.

    Article  PubMed  CAS  Google Scholar 

  110. Smedegard G, Cui LX, Hugh TE: Endotoxin-induced shock in the rat: a role for C5a. Am J Pathol 1989; 135: 489–497.

    PubMed  CAS  Google Scholar 

  111. Schmid E, Piccolo MT, Friedl HP, et al: Requirement for C5a in lung vascular injury following thermal trauma to rat skin. Shock 1997; 8: 119–124.

    Article  PubMed  CAS  Google Scholar 

  112. Bless NM, Warner RL, Padgaonkar VA, et al: Roles of C-X-C chemokines and C5a in lung injury after hindlimb ischemia/ reperfusion. Am J Physiol 1999; 276: 57–63.

    Google Scholar 

  113. Amsterdam EA, Stahl GL, Pan HL, et al: Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: 448–457.

    Google Scholar 

  114. Höpken U, Mohr M, Strüber A, et al: Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996; 26: 1103–1109.

    Article  PubMed  Google Scholar 

  115. Mohr M, Höpken U, Oppermann M, et al: Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 1998; 28: 227–234.

    Article  PubMed  CAS  Google Scholar 

  116. Ames RS, Tornetta MA, Jones CS, et al: Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J Immunol 1994; 153: 910.

    PubMed  CAS  Google Scholar 

  117. Kola A, Baensch M, Bautsch W, et al: Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis. Immunotechnology 1996; 2: 115–126.

    Article  PubMed  CAS  Google Scholar 

  118. Pellas TC, Boyar W, van Oostrum J, et al: Novel G5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J. Immunol 1998; 160: 5616–5621.

    PubMed  CAS  Google Scholar 

  119. Heller T, Hennecke M, Baensch M, et al: A C5a mutant selected from a phage library is a potent C5a-receptor antagonist in vitro and in vivo. Mol Immunol 1998; 35: 365A.

    Article  Google Scholar 

  120. Morgan EL, Ember JA, Sanderson SD, et al: Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, G5aR-(9-29), derived from the predicted aminoterminal sequence of the human G5a receptor. J Immunol 1993; 151: 377–388.

    PubMed  CAS  Google Scholar 

  121. Lanza TJ, Durette PL, Rollins T, et al: Substituted 4, 6-diaminoquinolines as inhibitors of G5a receptor binding. J Med Chem 1992; 35: 252–258.

    Article  PubMed  CAS  Google Scholar 

  122. Inagi R, Miyata T, Maeda K, et al: FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett 1991; 27: 49–52.

    Article  PubMed  CAS  Google Scholar 

  123. Araida T, Frey CF, Ruebner B, et al: Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics. Pancreas 1995; 11: 132–140.

    Article  PubMed  CAS  Google Scholar 

  124. Homeister JW, Satoh P, Lueehesi BR: Effects of complement activation in the isolated heart: role of tiie terminal complement components. Circ Res 1992; 71: 303–319.

    Article  PubMed  CAS  Google Scholar 

  125. Blum MG, Coffins BJ, Chang AC, et al: Complement inhibition by FUT-175 and K76-COOH in a pig-to-human lung xenotransplant model. Xenotransplantation 1998; 5: 35–43.

    Article  PubMed  CAS  Google Scholar 

  126. Cheung AK, Parker CJ, Janatova J, et al: Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Nephrol 1992; 2: 1328–1337.

    PubMed  CAS  Google Scholar 

  127. Moen O, Hogasen K, Fosse E, et al: Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 105–111.

    Article  PubMed  CAS  Google Scholar 

  128. Schreurs HH, Wijers MJ, Gu YJ, et al: Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations. Ann Thorac Surg 1998; 66: 166–171.

    Article  PubMed  CAS  Google Scholar 

  129. Miletic VD, Hester CG, Frank MM: Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996; 156: 749–757.

    PubMed  CAS  Google Scholar 

  130. Lutz HU, Stammler P, Jelezarova E, et al: High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn—IgG complexes. Blood 1996; 88: 184–193.

    PubMed  CAS  Google Scholar 

  131. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729–1735.

    Article  PubMed  CAS  Google Scholar 

  132. Fritzinger DC, Bredehorst R, Vogel CW: Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci USA 1994; 91: 12775–12779.

    Article  PubMed  CAS  Google Scholar 

  133. Cochrane CG, Müller-Eberhard HJ, Aikin BS: Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 1970; 105: 55–69.

    PubMed  CAS  Google Scholar 

  134. Ren XD, Huang SJ, Sun JJ, et al: Protective effect of cobra venom factor on pulmonary injury induced by oleic acid. Int J Immu-nopharmacol 1994; 16: 969–975.

    Article  CAS  Google Scholar 

  135. Dehring DJ, Steinberg SM, Wismar BL, et al: Complement depletion in a porcine model of septic acute respiratory disease. J Trauma 1987; 27: 615–625.

    Article  PubMed  CAS  Google Scholar 

  136. Vriesendorp FJ, Flynn RE, Pappolla MA, et al: Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J Neuroimmunol 1995; 58: 157–165.

    Article  PubMed  CAS  Google Scholar 

  137. Mathieson PW, Qasim FJ, Thiru S, et al: Effects of decomple-mentation with cobra venom factor on experimental vasculitis. Clin Exp Immunol 1994; 97: 474–477.

    Article  PubMed  CAS  Google Scholar 

  138. Gewurz H, Clark DS, Cooper MD, et al: Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5: 1296–1303.

    Article  PubMed  CAS  Google Scholar 

  139. Chrupcaila M, Pomer S, Staehler G, et al: Prolongation of discordant renal xenograft survival by depletion of complement: comparative effects of systematically administered cobra venom factor and soluble complement receptor type 1 in a guinea pig-to-rat model. Transplant Int 1994; 7: 650–653.

    Article  Google Scholar 

  140. Azimzadeh A, Wolf P, Dalmasso AP, et al: Assessment of hyperacute rejection in a rat-to-primate cardiac xenograft model. Transplantation 1996; 61: 1305–1313.

    Article  PubMed  CAS  Google Scholar 

  141. Platt JL, Bach FH: The barrier to xenotransplantation. Transplantation 1991; 52: 937–947.

    Article  PubMed  CAS  Google Scholar 

  142. Dalmasso AP: The complement system in xenotransplantation. Immunopharmacology 1992; 24: 149–160.

    Article  PubMed  CAS  Google Scholar 

  143. Kirschfink M, Haferkamp A, Pomer S, et al: Significance of the complement system for xenotransplantation: strategies for therapeutic intervention. Zentralbl Chir 1998; 123: 793–797.

    PubMed  CAS  Google Scholar 

  144. Dalmasso AP, Vercellotti GM, Piatt JL, et al: Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530–533.

    Article  PubMed  CAS  Google Scholar 

  145. Heckl-Östreicher B, Wosnik A, Kirschfink M: Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1: analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation 1996; 62: 1693–1696.

    Article  PubMed  Google Scholar 

  146. Kooyman DL, Byrne GW, McClellan S, et al: In vivo transfer of GPI-linked complement restriction factor from erythrocytes to the endothelium. Science 1995; 269: 89–92.

    Article  PubMed  CAS  Google Scholar 

  147. Gozzi E, White DJ: The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964–966.

    Article  Google Scholar 

  148. Kroshus TJ, Bolman RM III, Dalmasso AP: Studies on transfer of primate membrane-associated complement inhibitors from recipient blood to porcine donor organs. Transplant Proc 1996; 28: 601–602.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Katrin Jurianz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kirschfink
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, St. Louis University Hospital, St. Louis, Missouri, 63110, USA

    Arthur E. Baue MD (Professor Emeritus) (Professor Emeritus)

  2. Department of Surgery, Klinikum Grosshadern, University of Munich, Munich, D-81377, Germany

    Eugen Faist MD (Professor) (Professor)

  3. Department of Surgery, School of Medicine, University of New Mexico, Albuquerque, New Mexico, 87131, USA

    Donald E. Fry MD (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jurianz, K., Kirschfink, M. (2000). Therapeutic Complement Inhibition. In: Baue, A.E., Faist, E., Fry, D.E. (eds) Multiple Organ Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1222-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1222-5_23

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7049-2

  • Online ISBN: 978-1-4612-1222-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation